Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles

Trends in Molecular Medicine

Volumn 21, Issue 10, 2015, Pages 595-608

  Sousa, Diana ^a,b   Lima, Raquel T ^a,b,c   Vasconcelos, M Helena ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; LONG UNTRANSLATED RNA; MICRORNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN;

CANCER RESISTANCE; CELL TRANSFER; DRUG RESISTANCE; EXOSOME; HUMAN; MEMBRANE MICROPARTICLE; NONHUMAN; PHENOTYPE; REGULATORY MECHANISM; REVIEW; ANIMAL; CELL COMMUNICATION;

ANIMALS; CELL COMMUNICATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR VESICLES; HUMANS;

EID: 84942521471     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.08.002     Document Type: Review

References (78)

1. Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front. Pharmacol. 2013, 4:21.
2. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 2013, 200:373-383.
3. El Andaloussi S., et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12:347-357.
4. Peinado H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
5. Luga V., et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151:1542-1556.
6. Al-Nedawi K., et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3794-3799.
7. Ashiru O., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70:481-489.
8. Azmi A.S., et al. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
9. Takahashi K., et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014, 4:458-467.
10. Takahashi K., et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol. Cancer Res. 2014, 12:1377-1387.
11. Gong J., et al. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur. J. Pharmacol. 2013, 721:116-125.
12. Ifergan I., et al. Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells. Biochem. Biophys. Res. Commun. 2009, 380:5-10.
13. Parolini I., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 2009, 284:34211-34222.
14. De Milito A., Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005, 1:779-786.
15. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J. Intern. Med. 2010, 267:515-525.
16. Spugnini E.P., et al. Proton channels and exchangers in cancer. Biochim. Biophys. Acta. 2014, Published online October 20, 2014. 10.1016/j.bbamem.2014.10.015.
17. Jaiswal R., et al. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS ONE 2013, 8:e61515.
18. Goler-Baron V., et al. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem. Pharmacol. 2012, 83:1340-1348.
19. Kharaziha P., et al. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 2015, (in press).
20. Beloribi-Djefaflia S., et al. Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1α signaling axis. Oncoscience 2015, 2:15-30.
21. Ifergan I., et al. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res. 2005, 65:10952-10958.
22. Zhao L., et al. The role of exosomes and "exosomal shuttle microRNA" in tumorigenesis and drug resistance. Cancer Lett. 2015, 356:339-346.
23. Jaiswal R., et al. Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol. 2014, 10:655-669.
24. Lopes-Rodrigues V., et al. The network of P-glycoprotein and microRNAs interactions. Int. J. Cancer 2014, 135:253-263.
25. Pasquier J., et al. Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol. Direct 2011, 6:5.
26. Levchenko A., et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1933-1938.
27. Rafii A., et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS ONE 2008, 3:e3894.
28. Bebawy M., et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009, 23:1643-1649.
29. Corcoran C., et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS ONE 2012, 7:e50999.
30. Lv M.M., et al. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014, 35:10773-10779.
31. Zhang F.F., et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur. J. Pharmacol. 2014, 738:83-90.
32. de Souza P.S., et al. Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type. Cancer Sci. 2015, 106:60-68.
33. Lu J.F., et al. Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol. Res. 2013, 76:77-83.
34. Goler-Baron V., Assaraf Y.G. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS ONE 2011, 6:e16007.
35. Goler-Baron V., Assaraf Y.G. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS ONE 2012, 7:e35487.
36. Kong J.N., et al. Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells. Int. J. Cancer 2015, 137:1610-1620.
37. Colombo M., et al. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30:255-289.
38. Chapuy B., et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008, 22:1576-1586.
39. Aung T., et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15336-15341.
40. To K.K. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J. Biomed. Sci. 2013, 20:99.
41. Yan F., et al. Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation. Cell Death Dis. 2014, 5:e1413.
42. Gao W., et al. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol. Ther. 2012, 13:330-340.
43. Pignot G., et al. MicroRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int. J. Cancer 2013, 132:2479-2491.
44. Lima R.T., et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur. J. Cancer 2011, 47:163-174.
45. Seca H., et al. miR signatures and the role of miRs in acute myeloid leukaemia. Eur. J. Cancer 2010, 46:1520-1527.
46. Seca H., et al. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr. Drug Targets 2013, 14:1135-1143.
47. Koga Y., et al. Exosome can prevent RNase from degrading microRNA in feces. J. Gastrointest. Oncol. 2011, 2:215-222.
48. Skog J., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
49. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
50. Aushev V.N., et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS ONE 2013, 8:e78649.
51. Corcoran C., et al. Intracellular and extracellular microRNAs in breast cancer. Clin. Chem. 2011, 57:18-32.
52. Corcoran C., et al. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 2014, 74:1320-1334.
53. Rabinowits G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
54. Xiao D., et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS ONE 2012, 7:e46874.
55. Xiao X., et al. Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PLoS ONE 2014, 9:e89534.
56. Jaiswal R., et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J. 2012, 26:420-429.
57. Chen W.X., et al. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014, 35:9649-9659.
58. Chen W.X., et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS ONE 2014, 9:e95240.
59. Wei Y., et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 2014, 147:423-431.
60. Akao Y., et al. Extracellular disposal of tumor-suppressor miRs-145 and -34a via microvesicles and 5-FU resistance of human colon cancer cells. Int. J. Mol. Sci. 2014, 15:1392-1401.
61. Lucotti S., et al. Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival. Mol. Cancer 2013, 12:52.
62. Gong J., et al. Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells. Front. Oncol. 2014, 4:220.
63. Jaiswal R., et al. Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol. Cancer 2012, 11:37.
64. Melo S.A., et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014, 26:707-721.
65. Li L., et al. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS ONE 2012, 7:e46957.
66. Gezer U., et al. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol. Int. 2014, 38:1076-1079.
67. Biswas S., et al. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 2007, 117:1305-1313.
68. Yan X., et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010, 70:1616-1624.
69. Yin J., et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J. Cell. Mol. Med. 2012, 16:337-348.
70. Dong Y., et al. Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells. Biochem. Biophys. Res. Commun. 2014, 446:85-90.
71. Ma X., et al. Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:6389-6394.
72. Maloney D.G., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457-2466.
73. Bentires-Alj M., et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
74. Lai C.P., et al. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 2015, 6:7029.
75. Shao H., et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat. Commun. 2015, 6:6999.
76. Gyorgy B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 2011, 68:2667-2688.
77. Gould S.J., Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicles 2013, Published online February 15, 2013. 10.3402/jev.v2i0.20389.
78. Takahashi K., et al. Involvement of extracellular vesicle long non-coding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol. Cancer Res. 2014, 12:1377-1387.